Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C28H36O15 |
| Molecular Weight | 612.5764 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 10 / 10 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(O)C=C(CCC(=O)C2=C(O)C=C(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)C=C2O)C=C1
InChI
InChIKey=ITVGXXMINPYUHD-CUVHLRMHSA-N
InChI=1S/C28H36O15/c1-11-21(34)23(36)25(38)27(40-11)43-26-24(37)22(35)19(10-29)42-28(26)41-13-8-16(32)20(17(33)9-13)14(30)5-3-12-4-6-18(39-2)15(31)7-12/h4,6-9,11,19,21-29,31-38H,3,5,10H2,1-2H3/t11-,19+,21-,22+,23+,24-,25+,26+,27-,28+/m0/s1
| Molecular Formula | C28H36O15 |
| Molecular Weight | 612.5764 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 10 / 10 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/24530446Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/26362205 | https://www.ncbi.nlm.nih.gov/pubmed/26453923
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24530446
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/26362205 | https://www.ncbi.nlm.nih.gov/pubmed/26453923
Neohesperidin dihydrochalcone is a semi-synthetic glycoside chalcone, which is produced by catalytic hydrogenation of neohesperidin, themain flavanone glycoside of bitter oranges. Neohesperidin dihydrochalcone has wide application in various foods and beverages as a low caloric artificial sweetener. Neohesperidin dihydrochalcone is well tolerated and is not associated with any particular toxicity as a well-known sweetener. No adverse effects were observed at Neohesperidin dihydrochalcone levels of up to 5% of the diet of Wistar rats in embryotoxicity and teratogenicity studies. The mutagenicity of Neohesperidin dihydrochalcone was assessed in different experimental models, and no mutagenic activity was detected. Neohesperidin dihydrochalcone showed outstanding antioxidant and radical scavenging activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0034125 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26453923 |
|||
Target ID: GO:0034128 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26453923 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26362205
Neohesperidin dihydrochalcone (200 mg/kg body weight, dissolved in a 0.5% CMC vehicle and prepared before use) was administrated to Male Kunmingmice by oral gavage for 6 consecutive days.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24530446
The human hepatoma cell line (HepG2) was treated with Neohesperidin dihydrochalcone (10, 20 or 30 mkM) for 1 h
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:51:54 GMT 2025
by
admin
on
Mon Mar 31 17:51:54 GMT 2025
|
| Record UNII |
3X476D83QV
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
3X476D83QV
Created by
admin on Mon Mar 31 17:51:54 GMT 2025 , Edited by admin on Mon Mar 31 17:51:54 GMT 2025
|
PRIMARY | |||
|
20702-77-6
Created by
admin on Mon Mar 31 17:51:54 GMT 2025 , Edited by admin on Mon Mar 31 17:51:54 GMT 2025
|
PRIMARY | |||
|
m7807
Created by
admin on Mon Mar 31 17:51:54 GMT 2025 , Edited by admin on Mon Mar 31 17:51:54 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID3025706
Created by
admin on Mon Mar 31 17:51:54 GMT 2025 , Edited by admin on Mon Mar 31 17:51:54 GMT 2025
|
PRIMARY | |||
|
100000079589
Created by
admin on Mon Mar 31 17:51:54 GMT 2025 , Edited by admin on Mon Mar 31 17:51:54 GMT 2025
|
PRIMARY | |||
|
30231
Created by
admin on Mon Mar 31 17:51:54 GMT 2025 , Edited by admin on Mon Mar 31 17:51:54 GMT 2025
|
PRIMARY | |||
|
NEOHESPERIDIN DIHYDROCHALCONE
Created by
admin on Mon Mar 31 17:51:54 GMT 2025 , Edited by admin on Mon Mar 31 17:51:54 GMT 2025
|
PRIMARY | |||
|
C013613
Created by
admin on Mon Mar 31 17:51:54 GMT 2025 , Edited by admin on Mon Mar 31 17:51:54 GMT 2025
|
PRIMARY | |||
|
902
Created by
admin on Mon Mar 31 17:51:54 GMT 2025 , Edited by admin on Mon Mar 31 17:51:54 GMT 2025
|
PRIMARY | |||
|
1312741
Created by
admin on Mon Mar 31 17:51:54 GMT 2025 , Edited by admin on Mon Mar 31 17:51:54 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB12169MIG
Created by
admin on Mon Mar 31 17:51:54 GMT 2025 , Edited by admin on Mon Mar 31 17:51:54 GMT 2025
|
PRIMARY | |||
|
243-978-6
Created by
admin on Mon Mar 31 17:51:54 GMT 2025 , Edited by admin on Mon Mar 31 17:51:54 GMT 2025
|
PRIMARY | |||
|
1458086
Created by
admin on Mon Mar 31 17:51:54 GMT 2025 , Edited by admin on Mon Mar 31 17:51:54 GMT 2025
|
PRIMARY | |||
|
3X476D83QV
Created by
admin on Mon Mar 31 17:51:54 GMT 2025 , Edited by admin on Mon Mar 31 17:51:54 GMT 2025
|
PRIMARY |